TAC-001
Phase 2Small molecule
TAC-001 is one of 35 small molecule programs targeting Advanced or Metastatic Solid Tumors. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
34
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
62 competitors in Advanced or Metastatic Solid Tumors
#DrugCompanyPhaseTrials
1Keytruda
Merck & Co.Phase 2
Avastin
RochePhase 2
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 2
Gemzar
Johnson & JohnsonPhase 1
Adriamycin
PfizerPhase 1
Vectibix
AmgenPhase 1
Taxane
Bristol-Myers SquibbPhase 2
Standard Treatment
Boehringer IngelheimPhase 2
MHB036C
MMinghui Pharmaceutical (Hangzhou) Ltd
Phase 2
Taxotere
AAvyxa
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for TAC-001. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- TTallac Therapeutics